A CRISPR-Cas9 Monograph: The Potency of Targeted Genome Modulation In Vivo
17 Pages Posted: 23 Nov 2018
Date Written: April 20th, 2018
In recent years, with the rise of numerous genetic disorders and autoimmune diseases, researchers have pioneered the CRISPR-Cas9 system as an economical, convenient, and scalable gene therapy treatment. Originally modeled, or identified, in Haloferax mediterranei by Francisco Mojica PhD at the University of Alicante in 1992, the CRISPR-Cas9 is effectively able to modify DNA in vivo. For example, studies abroad have selectively altered mutations in the MYBPC3 gene to help patients with embryonic hypertrophic cardiomyopathy. It is important to note that just as this system will largely impact the scientific community after its formal approval, so too will it affect much of the legislation, business, commerce, and lifestyle of the future. This monograph assesses the microscopic and macroscopic features of the CRISPR-Cas9 system meticulously by sequence analysis and literature review to determine the potential of this experimental field.
Keywords: Review, Genomics, CRISPR, Biochemistry, Molecular Biology, Oncology, Neuroscience, DNA
JEL Classification: I12
Suggested Citation: Suggested Citation